743 related articles for article (PubMed ID: 26005866)
21. Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.
Rubin MA; Girelli G; Demichelis F
Eur Urol; 2016 Apr; 69(4):557-560. PubMed ID: 26563871
[TBL] [Abstract][Full Text] [Related]
22. Next generation mapping reveals novel large genomic rearrangements in prostate cancer.
Jaratlerdsiri W; Chan EKF; Petersen DC; Yang C; Croucher PI; Bornman MSR; Sheth P; Hayes VM
Oncotarget; 2017 Apr; 8(14):23588-23602. PubMed ID: 28423598
[TBL] [Abstract][Full Text] [Related]
23. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma.
Xu LX; He MH; Dai ZH; Yu J; Wang JG; Li XC; Jiang BB; Ke ZF; Su TH; Peng ZW; Guo Y; Chen ZB; Chen SL; Peng S; Kuang M
Ann Oncol; 2019 Jun; 30(6):990-997. PubMed ID: 30916311
[TBL] [Abstract][Full Text] [Related]
24. Genomic hallmarks of localized, non-indolent prostate cancer.
Fraser M; Sabelnykova VY; Yamaguchi TN; Heisler LE; Livingstone J; Huang V; Shiah YJ; Yousif F; Lin X; Masella AP; Fox NS; Xie M; Prokopec SD; Berlin A; Lalonde E; Ahmed M; Trudel D; Luo X; Beck TA; Meng A; Zhang J; D'Costa A; Denroche RE; Kong H; Espiritu SM; Chua ML; Wong A; Chong T; Sam M; Johns J; Timms L; Buchner NB; Orain M; Picard V; Hovington H; Murison A; Kron K; Harding NJ; P'ng C; Houlahan KE; Chu KC; Lo B; Nguyen F; Li CH; Sun RX; de Borja R; Cooper CI; Hopkins JF; Govind SK; Fung C; Waggott D; Green J; Haider S; Chan-Seng-Yue MA; Jung E; Wang Z; Bergeron A; Dal Pra A; Lacombe L; Collins CC; Sahinalp C; Lupien M; Fleshner NE; He HH; Fradet Y; Tetu B; van der Kwast T; McPherson JD; Bristow RG; Boutros PC
Nature; 2017 Jan; 541(7637):359-364. PubMed ID: 28068672
[TBL] [Abstract][Full Text] [Related]
25. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
26. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
[TBL] [Abstract][Full Text] [Related]
27. Multiple Origin and Tumor Heterogeneity of Prostatic Ductal Adenocarcinoma in the Han Chinese Population.
Zhang W; Su F; Wang M; Hou H; Liu M; Liu D; Liu H
Genet Test Mol Biomarkers; 2021 Nov; 25(11):727-732. PubMed ID: 34788144
[No Abstract] [Full Text] [Related]
28. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.
Jiang R; Lu YT; Ho H; Li B; Chen JF; Lin M; Li F; Wu K; Wu H; Lichterman J; Wan H; Lu CL; OuYang W; Ni M; Wang L; Li G; Lee T; Zhang X; Yang J; Rettig M; Chung LW; Yang H; Li KC; Hou Y; Tseng HR; Hou S; Xu X; Wang J; Posadas EM
Oncotarget; 2015 Dec; 6(42):44781-93. PubMed ID: 26575023
[TBL] [Abstract][Full Text] [Related]
29. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
30. Copy number alterations in prostate tumors and disease aggressiveness.
Cheng I; Levin AM; Tai YC; Plummer S; Chen GK; Neslund-Dudas C; Casey G; Rybicki BA; Witte JS
Genes Chromosomes Cancer; 2012 Jan; 51(1):66-76. PubMed ID: 21965145
[TBL] [Abstract][Full Text] [Related]
31. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
[TBL] [Abstract][Full Text] [Related]
32. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
33. The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma.
Bianchi-Frias D; Hernandez SA; Coleman R; Wu H; Nelson PS
Mol Cancer Res; 2015 Feb; 13(2):339-47. PubMed ID: 25298407
[TBL] [Abstract][Full Text] [Related]
34. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer.
Brocks D; Assenov Y; Minner S; Bogatyrova O; Simon R; Koop C; Oakes C; Zucknick M; Lipka DB; Weischenfeldt J; Feuerbach L; Cowper-Sal Lari R; Lupien M; Brors B; Korbel J; Schlomm T; Tanay A; Sauter G; Gerhäuser C; Plass C;
Cell Rep; 2014 Aug; 8(3):798-806. PubMed ID: 25066126
[TBL] [Abstract][Full Text] [Related]
35. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Quigley DA; Dang HX; Zhao SG; Lloyd P; Aggarwal R; Alumkal JJ; Foye A; Kothari V; Perry MD; Bailey AM; Playdle D; Barnard TJ; Zhang L; Zhang J; Youngren JF; Cieslik MP; Parolia A; Beer TM; Thomas G; Chi KN; Gleave M; Lack NA; Zoubeidi A; Reiter RE; Rettig MB; Witte O; Ryan CJ; Fong L; Kim W; Friedlander T; Chou J; Li H; Das R; Li H; Moussavi-Baygi R; Goodarzi H; Gilbert LA; Lara PN; Evans CP; Goldstein TC; Stuart JM; Tomlins SA; Spratt DE; Cheetham RK; Cheng DT; Farh K; Gehring JS; Hakenberg J; Liao A; Febbo PG; Shon J; Sickler B; Batzoglou S; Knudsen KE; He HH; Huang J; Wyatt AW; Dehm SM; Ashworth A; Chinnaiyan AM; Maher CA; Small EJ; Feng FY
Cell; 2018 Jul; 174(3):758-769.e9. PubMed ID: 30033370
[TBL] [Abstract][Full Text] [Related]
36. Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients.
Ronowicz A; Janaszak-Jasiecka A; Skokowski J; Madanecki P; Bartoszewski R; Bałut M; Seroczyńska B; Kochan K; Bogdan A; Butkus M; Pęksa R; Ratajska M; Kuźniacka A; Wasąg B; Gucwa M; Krzyżanowski M; Jaśkiewicz J; Jankowski Z; Forsberg L; Ochocka JR; Limon J; Crowley MR; Buckley PG; Messiaen L; Dumanski JP; Piotrowski A
Hum Mutat; 2015 Nov; 36(11):1088-99. PubMed ID: 26219265
[TBL] [Abstract][Full Text] [Related]
37. Copy number alteration burden predicts prostate cancer relapse.
Hieronymus H; Schultz N; Gopalan A; Carver BS; Chang MT; Xiao Y; Heguy A; Huberman K; Bernstein M; Assel M; Murali R; Vickers A; Scardino PT; Sander C; Reuter V; Taylor BS; Sawyers CL
Proc Natl Acad Sci U S A; 2014 Jul; 111(30):11139-44. PubMed ID: 25024180
[TBL] [Abstract][Full Text] [Related]
38. Accurate quantification of copy-number aberrations and whole-genome duplications in multi-sample tumor sequencing data.
Zaccaria S; Raphael BJ
Nat Commun; 2020 Sep; 11(1):4301. PubMed ID: 32879317
[TBL] [Abstract][Full Text] [Related]
39. Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.
Alexander J; Kendall J; McIndoo J; Rodgers L; Aboukhalil R; Levy D; Stepansky A; Sun G; Chobardjiev L; Riggs M; Cox H; Hakker I; Nowak DG; Laze J; Llukani E; Srivastava A; Gruschow S; Yadav SS; Robinson B; Atwal G; Trotman LC; Lepor H; Hicks J; Wigler M; Krasnitz A
Cancer Res; 2018 Jan; 78(2):348-358. PubMed ID: 29180472
[TBL] [Abstract][Full Text] [Related]
40. Copy number alterations are associated with metastatic-lethal progression in prostate cancer.
Wang X; Grasso CS; Jordahl KM; Kolb S; Nyame YA; Wright JL; Ostrander EA; Troyer DA; Lance R; Feng Z; Dai JY; Stanford JL
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):494-506. PubMed ID: 32071439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
